API | daridorexant

daridorexant (Quviviq) Report issue

Small molecule Approved ^FDA

AACT PubChem

Active Ingredient History

NOW

Now

Chemistry

SMILES: COc1ccc(-n2nccn2)c(C(=O)N2CCC[C@@]2(C)c2nc3c(C)c(Cl)ccc3[nH]2)c1
InChIKey: NBGABHGMJVIVBW-QHCPKHFHSA-N
Mol. Mass: 450.93
ALogP: 4.27 Partition coefficient
ChEMBL Molecules:

daridorexant

daridorexant hydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Orexin receptor type 1 (Homo sapiens) ^UniProt
- Orexin receptor type 2 (Homo sapiens) ^UniProt
- Orexin receptor type 1 (Homo sapiens) ^UniProt
- Orexin receptor type 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

act-541468

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (2)

Sleep Disorders, Circadian Rhythm (approved 2022)

Sleep Initiation and Maintenance Disorders

Experimental Indications - Clinical Trial Phases 1-4 (10)

Alzheimer Disease (Phase 4)

Healthy Volunteers (Phase 1)

Liver Diseases (Phase 1)

Nocturia (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Renal Insufficiency (Phase 1)

Sleep (Phase 4)

Sleep Apnea, Obstructive (Phase 1)

Sleep Initiation and Maintenance Disorders (Phase 4)

Stress Disorders, Post-Traumatic (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 33
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue